Nivolumab/Ipilimumab-Primed Immunotransplant for DLBCL
A Multi-center Phase Ib/II Trial of Nivolumab/Ipilimumab-Primed Immunotransplant for Relapsed/Refractory Diffuse Large B Cell Lymphoma Patients.
Sponsor: Bristol-Myers Squibb
This PHASE1 trial investigates Refractory Diffuse Large B-Cell Lymphoma and Relapsed Diffuse Large B-Cell Lymphoma and is currently completed. Bristol-Myers Squibb leads this study, which shows 12 recorded versions since 2018 — indicating substantial longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Mar 2023 — Jul 2024 [monthly]
Completed PHASE1
Phase: PHASE1_PHASE2 → PHASE1
-
May 2022 — Mar 2023 [monthly]
Completed PHASE1_PHASE2
Status: Recruiting → Completed
-
Jan 2021 — May 2022 [monthly]
Recruiting PHASE1_PHASE2
▶ Show 7 earlier versions
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE1_PHASE2
-
Nov 2020 — Dec 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jan 2020 — Nov 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2019 — Jan 2020 [monthly]
Recruiting PHASE1_PHASE2
-
Jun 2018 — Jun 2019 [monthly]
Recruiting PHASE1_PHASE2
-
Mar 2018 — Jun 2018 [monthly]
Recruiting PHASE1_PHASE2
Status: Not Yet Recruiting → Recruiting
-
Oct 2017 — Mar 2018 [monthly]
Not Yet Recruiting PHASE1_PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bristol-Myers Squibb
- Icahn School of Medicine at Mount Sinai
For direct contact, visit the study record on ClinicalTrials.gov .